AAD Licensed Content

The speaker argues that IL-17 is the better target than IL-23 for preventing and treating psoriatic arthritis, emphasizing that the decision should be based on data rather than narrative. He says psoriatic…

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Argument for IL-17 Over IL-23 in Psoriatic Arthritis Prevention and Treatment

Description

The speaker argues that IL-17 is the better target than IL-23 for preventing and treating psoriatic arthritis, emphasizing that the decision should be based on data rather than narrative. He says psoriatic arthritis is mechanistically heterogeneous and involves IL-17 production from multiple immune pathways not fully controlled by IL-23, including mast cells, innate lymphoid cells, and gamma-delta cells, especially in synovial fluid and enthesis-related disease. He notes that IL-17 appears important across multiple disease domains, including axial disease, where IL-23 has not shown efficacy and is not recommended in guidelines. He also points to current efficacy evidence, saying IL-17 inhibitors generally perform better and citing a head-to-head study in which bimekizumab outperformed an IL-23 approach across endpoints, while transcriptomic findings suggested IL-17 blockade can downregulate IL-23, implying a feedback loop rather than a simple downstream pathway. He cautions that observational prevention studies favoring IL-23 may be biased by channeling and protopathic bias, since patients with early joint symptoms may have been preferentially placed on IL-17 or TNF drugs. Although he acknowledges emerging prospective prevention/interception data, he concludes that the mechanistic and efficacy data currently favor IL-17, urging the audience to vote based on the numbers and choose IL-17.

View more

Conclusions

  • The presentation argues that IL-17 inhibition should be prioritized over IL-23 inhibition when the goal is preventing psoriatic arthritis.
  • Psoriatic arthritis appears biologically heterogeneous, with important IL-17 activity that can arise independently of IL-23.
  • Because different PsA domains are driven by different pathways, a treatment that works broadly across peripheral arthritis, enthesitis, dactylitis, axial disease, and radiographic outcomes is preferred.
  • The speaker concludes that IL-17 inhibitors currently have stronger established efficacy across PsA domains than IL-23 inhibitors.
  • Recent head-to-head and transcriptomic data are presented as evidence that IL-17 blockade can outperform IL-23 blockade and may even downregulate IL-23 expression.
  • The observational studies suggesting IL-23 benefit are viewed as vulnerable to confounding, channeling bias, and protopathic bias, so they are considered insufficient for firm conclusions.
  • Early interception and prospective data are interpreted as suggestive that IL-17 inhibition may reduce symptoms or subclinical inflammation in high-risk psoriasis patients.
  • Overall, the talk concludes that the weight of current evidence favors IL-17 inhibitors as the best first choice for PsA prevention, while acknowledging that definitive prospective prevention trials are still needed.
  • Nature Reviews Rheumatology | Volume 21 | April 2025 | 237-248
  • GRAPPA 2021 recommendations
  • Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis#10.1136/ard-2024-225534
  • Interleukin-23 versus Interleukin-17 Inhibitors in Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis: A Real-World Comparison From the TriNetX US Collaborative Network#10.1007/s40259-025-00705-5